{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sarna",
    "query": {
      "intervention": "Sarna"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T10:11:27.834Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05227001",
      "title": "A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "PF-07852352 Influenza saRNA 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PF-07836391 Influenza saRNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PF-07836394 Influenza saRNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PF-07836395 Influenza saRNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PF-07836396 Influenza saRNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PF-07867246 Influenza saRNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent influenza vaccine (QIV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PF-07871987 Influenza saRNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PF-07914705 Influenza saRNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PF-07915048 Influenza saRNA",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 440,
      "start_date": "2022-04-28",
      "completion_date": "2023-08-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-09-07T10:11:27.834Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Walnut Creek, California • Greenacres City, Florida + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Greenacres City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05227001"
    },
    {
      "nct_id": "NCT07652242",
      "title": "Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer (TNBC)"
      ],
      "interventions": [
        {
          "name": "ITI-5000 mRNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "ITI-5000 MTD (Maximum Tolerated Dose)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Immunomic Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2026-06",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-09-07T10:11:27.834Z",
      "location_count": 2,
      "location_summary": "Grand Rapids, Michigan • Nashville, Tennessee",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07652242"
    },
    {
      "nct_id": "NCT06736379",
      "title": "Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancers- Squamous Cell",
        "Head and Neck Cancer",
        "Solid Tumors",
        "HNSCC",
        "SCC - Squamous Cell Carcinoma",
        "SCCHN",
        "Head Neck Cancer",
        "Head and Neck Squamous Cell Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Squamous Cell Carcinoma, Head And Neck",
        "Squamous Cell Head and Neck Carcinoma",
        "Oral Cavity",
        "Oral Cavity Carcinoma"
      ],
      "interventions": [
        {
          "name": "VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        },
        {
          "name": "VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "VLP Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2025-05-13",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-09-07T10:11:27.834Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06736379"
    },
    {
      "nct_id": "NCT04710641",
      "title": "Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Hepatitis B",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "MTL-CEBPA",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mina Alpha Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2022-01-01",
      "completion_date": "2025-01-25",
      "has_results": false,
      "last_update_posted_date": "2025-03-06",
      "last_synced_at": "2026-09-07T10:11:27.834Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04710641"
    },
    {
      "nct_id": "NCT00693654",
      "title": "Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pruritis"
      ],
      "interventions": [
        {
          "name": "Sarna",
          "type": "DRUG"
        },
        {
          "name": "Cetaphil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 28,
      "start_date": "2006-11",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2018-09-10",
      "last_synced_at": "2026-09-07T10:11:27.834Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00693654"
    }
  ]
}